Valsartan
Strives to synthesize a wide array of information, serving as a forum for discussion on litigation strategy, case criteria, and expert testimony.
Join Litigation GroupOn July 13, 2018, the FDA announced a Class I recall of certain batches of Valsartan, a drug used to treat hypertension and heart failure. The Valsartan Litigation Group strives to synthesize a wide array of information, serving as a forum for discussion on litigation strategy, case criteria, and expert testimony. Members will be kept up to date on the science and applicable law on the Valsartan litigation, receiving sample pleadings and group materials that incorporate recommendations from experts.
Litigation Group members, visit AAJ's Community Center to connect with your colleagues on the list server, search discussion archives, download documents, update your list server settings, and more. Lit Group Member Login
